Pharmacological therapy for myocardial reperfusion injury

被引:35
作者
Moukarbel, GV [1 ]
Ayoub, CM
Abchee, AB
机构
[1] Amer Univ Beirut, Dept Internal Med, Ctr Med, Beirut, Lebanon
[2] Amer Univ Beirut, Dept Anesthesiol, Ctr Med, Beirut, Lebanon
关键词
D O I
10.1016/j.coph.2003.10.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the ischemic myocardium, reperfusion is necessary for the salvage of cells and cardiac function. However, reperfusion itself causes 'reperfusion injury', leading to the damage of myocardial cells. This is reduced by several interventions, as measured by the limitation of infarct size or reduction of arrhythmias. Pharmacological agents that protect against injury include Na+/H+ exchanger inhibitors, antioxidants, calcium antagonists, renin-angiotensin system antagonists and adenosine. N-acetylcysteine, diltiazem, verapamil, enalaprilat and adenosine have all showed promising results in patients with acute myocardial infarction when given before reperfusion. Cariporide was beneficial when added to cardioplegia. However, their use in daily practice awaits results from large clinical trials.
引用
收藏
页码:147 / 153
页数:7
相关论文
共 69 条
[1]   Double-blind, randomized trial of an Anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction - Limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study [J].
Baran, KW ;
Nguyen, M ;
McKendall, GR ;
Lambrew, CT ;
Dykstra, G ;
Palmeri, ST ;
Gibbons, RJ ;
Borzak, S ;
Sobel, BE ;
Gourlay, SG ;
Rundle, AC ;
Gibson, CM ;
Barron, HV .
CIRCULATION, 2001, 104 (23) :2778-2783
[2]   Adenosine A1 agonist at reperfusion trial (AART):: Results of a three-center, blinded, randomized, controlled experimental infarct study [J].
Baxter, GF ;
Hale, SL ;
Miki, T ;
Kloner, RA ;
Cohen, MV ;
Downey, JM ;
Yellon, DM .
CARDIOVASCULAR DRUGS AND THERAPY, 2000, 14 (06) :607-614
[3]  
Belhomme D, 1999, CIRCULATION, V100, P340
[4]   Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: Results of the CABG surgery cohort of the GUARDIAN study [J].
Boyce, SW ;
Bartels, C ;
Bolli, R ;
Chaitman, B ;
Chen, JC ;
Chi, E ;
Jessel, A ;
Kereiakes, D ;
Knight, J ;
Thulin, L ;
Theroux, P .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 126 (02) :420-427
[5]   Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism [J].
Bradamante, S ;
Barenghi, L ;
Piccinini, F ;
Bertelli, AAE ;
De Jonge, R ;
Beemster, P ;
De Jong, JW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 465 (1-2) :115-123
[6]   CARDIOPROTECTIVE EFFECTS OF A C1 ESTERASE INHIBITOR IN MYOCARDIAL-ISCHEMIA AND REPERFUSION [J].
BUERKE, M ;
MUROHARA, T ;
LEFER, AM .
CIRCULATION, 1995, 91 (02) :393-402
[7]   Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits [J].
Buerke, M ;
Schwertz, H ;
Seitz, W ;
Meyer, J ;
Darius, H .
JOURNAL OF IMMUNOLOGY, 2001, 167 (09) :5375-5380
[8]   Aprotinin and preservation of myocardial function after ischemia-reperfusion injury [J].
Bull, DA ;
Maurer, J .
ANNALS OF THORACIC SURGERY, 2003, 75 (02) :S735-S739
[9]   Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction [J].
de Zwaan, C ;
Kleine, AH ;
Diris, JHC ;
Glatz, JFC ;
Wellens, HJJ ;
Strengers, PFW ;
Tissing, M ;
Hack, CE ;
van Dieijen-Visser, MP ;
Hermens, WT .
EUROPEAN HEART JOURNAL, 2002, 23 (21) :1670-1677
[10]   NEUTROPHIL ACCUMULATION IN ISCHEMIC CANINE MYOCARDIUM - INSIGHTS INTO TIME COURSE, DISTRIBUTION, AND MECHANISM OF LOCALIZATION DURING EARLY REPERFUSION [J].
DREYER, WJ ;
MICHAEL, LH ;
WEST, MS ;
SMITH, CW ;
ROTHLEIN, R ;
ROSSEN, RD ;
ANDERSON, DC ;
ENTMAN, ML .
CIRCULATION, 1991, 84 (01) :400-411